All In Biotech

Drug Trial Radar · NCT06627647

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,160

Planned (sponsor's estimate)

Start

Nov 27, 2024

Primary completion

Nov 18, 2030

Study completion Nov 18, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1.

Conditions

  • Non-squamous Non-small Cell Lung Cancer

Interventions

  • RilvegostomigDrug

    Administered as one intravenously (IV) on Day 1 of each 21-day cycle

  • PembrolizumabDrug

    Administered as one intravenously (IV) on Day 1 of each 21-day cycle

  • CarboplatinDrug

    Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles

  • CisplatinDrug

    Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles

  • PemetrexedDrug

    Administered as one intravenously (IV) on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Up to approximately 6 years
  2. Progression-free survival (PFS)Time frame: Up to approximately 6 years

Locations

301 sites in 25 countries. Site status is shown where the registry gives one.

  • Research Site

    Mobile, Alabama · Recruiting

  • Research Site

    Chandler, Arizona · Withdrawn

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Anaheim, California · Recruiting

  • Research Site

    Beverly Hills, California · Recruiting

  • Research Site

    Loma Linda, California · Recruiting

  • Research Site

    Redlands, California · Recruiting

  • Research Site

    San Diego, California · Recruiting

  • Research Site

    San Francisco, California · Recruiting

  • Research Site

    Santa Rosa, California · Recruiting

  • Research Site

    Walnut Creek, California · Recruiting

  • Research Site

    Lone Tree, Colorado · Recruiting

  • Research Site

    Stamford, Connecticut · Recruiting

  • Research Site

    West Haven, Connecticut · Recruiting

  • Research Site

    Newark, Delaware · Recruiting

  • Research Site

    Bay Pines, Florida · Recruiting

  • Research Site

    Fort Lauderdale, Florida · Recruiting

  • Research Site

    Gainesville, Florida · Withdrawn

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    Ocala, Florida · Recruiting

  • Research Site

    St. Petersburg, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Withdrawn

  • Research Site

    Boise, Idaho · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Decatur, Illinois · Recruiting

  • Research Site

    Hinsdale, Illinois · Recruiting

  • Research Site

    Quincy, Illinois · Recruiting

  • Research Site

    Rockford, Illinois · Withdrawn

  • Research Site

    Waterloo, Iowa · Recruiting

  • Research Site

    Lexington, Kentucky · Recruiting

  • Research Site

    Lexington, Kentucky · Withdrawn

  • Research Site

    Louisville, Kentucky · Recruiting

  • Research Site

    Alexandria, Louisiana · Withdrawn

  • Research Site

    Baton Rouge, Louisiana · Recruiting

  • Research Site

    Shreveport, Louisiana · Recruiting

  • Research Site

    Shreveport, Louisiana · Recruiting

  • Research Site

    South Portland, Maine · Recruiting

  • Research Site

    Baltimore, Maryland · Recruiting

  • Research Site

    Bethesda, Maryland · Not yet recruiting

Showing 40 of 301 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.